更新于：2024-12-19
Diclofenac Diethylamine
双氯芬酸二乙胺
更新于：2024-12-19
概要
基本信息
原研机构- |
在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C18H22Cl2N2O2 |
InChIKeyZQVZPANTCLRASL-UHFFFAOYSA-N |
CAS号78213-16-8 |
关联
35
项与 双氯芬酸二乙胺 相关的临床试验中国健康受试者涂抹双氯芬酸二乙胺乳胶剂的单中心、随机、开放、两制剂、单次给药、三序列、三周期，部分重复交叉设计生物等效性试验
双氯芬酸二乙胺乳胶剂人体生物等效性研究
双氯芬酸二乙胺乳胶剂人体生物等效性试验
100 项与 双氯芬酸二乙胺 相关的临床结果
登录后查看更多信息
100 项与 双氯芬酸二乙胺 相关的转化医学
登录后查看更多信息
100 项与 双氯芬酸二乙胺 相关的专利（医药）
登录后查看更多信息
114
项与 双氯芬酸二乙胺 相关的文献（医药）2024-12-01Therapeutic Delivery
Artemisinin emulgel ameliorates cartilage degradation in knee osteoarthritis:
in vitro
and
in vivo
studies
Article
作者: Arya, Shristi ; Kumar, Prashanth ; Guru, Santosh Kumar ; Singh, Hoshiyar ; Mourya, Atul ; Madan, Jitender ; Thote, Samiksha
Aim: Laboratory scale-up of artemisinin-loaded emulgel (ART-emulgel) was carried out and characterized for therapeutic performance in osteoarthritis (OA).Materials & methods: The solubility of ART in various oils, surfactants and co-surfactants were screened for construction of pseudo ternary phase diagram (TPD), followed by scale-up of artemisinin loaded nanoemulsion (ART-NE). ART-NE was amalgamated with Carbopol Ultrez 10-NF to prepare ART-emulgel that was later characterized in vitro and in vivo to analyze therapeutic efficacy in monosodium-iodoacetate (MIA) induced knee OA.Results: The droplet diameter of ART-NE was estimated to be 104.3 ± 2.593 nm with a polydispersity index of 0.245 ± 0.019 in addition to ζ-potential of 0.434 ± 0.028 mV. Steady-state flux and permeability coefficient for ART-emulgel were estimated to be 0.651 ± 0.031 µg.cm2/h and 0.245 ± 0.011 cm/h, respectively. ART-emulgel demonstrated 43.18% reduction in COX-2 level; 52.28% drop in IL-1β, and 88.78% alleviation of Tumor Necrosis Factor-α (TNF-α) level when compared with monosodium-iodoacetate induced OA rats. ART-emulgel and injectable ART (intra-articular; I.A) portrayed minor synovial erosion compared with blank and diclofenac emulgel. Histopathological evidences indicated restoration of cartilage integrity followed by reduction of OARSI scores in ART-emulgel when compared with disease control animals.Conclusion: ART-emulgel is a potential dosage form for translating into a clinically viable product for the management of OA.
2024-11-01Health Science Reports
The Role of Personalized Stenosing Tenosynovitis Brace Therapy Based on 3D Printing Technology: A Prospective Cohort Study
Article
作者: Dai, Jingjing ; Li, Xiaodong ; Sun, Guantong
ABSTRACT:
Objective:
To explore the clinical effect of personalized brace based on 3D printing technology in the treatment of stenosing tenosynovitis.
Methods:
From September 2021 to June 2023, 20 patients with stenosing tenosynovitis were collected and randomly divided into the experimental group and the control group, with 10 cases in each group, and each patient signed an informed consent. The experimental group was treated with personalized brace combined with External Diclofenac Diethalamine Emulgel, and the control group was treated with External Diclofenac Diethalamine Emulgel, and the clinical efficacy and pain scores of the two groups were compared.
Results:
After 8 weeks of treatment, the degree of pain relief, metacarpophalangeal joint mobility and proximal interphalangeal joint mobility of the experimental group were significantly higher than those of the control group. The activity pain scores of both groups were reduced, but the experimental group was significantly lower than the control group (p < 0.05).
Conclusion:
For the treatment of patients with stenosing tenosynovitis, it is recommended to use personalized stenosing tenosynovitis brace therapy based on 3D printing technology combined with External Diclofenac Diethalamine Emulgel at the first visit, which can significantly reduce finger pain and improve hand function.
2024-11-01CURRENT MOLECULAR MEDICINE
Hypothesizing the Oleic Acid-Mediated Enhanced and Sustained Transdermal Codelivery of Pregabalin and Diclofenac Adhesive Nanogel: A Proof of Concept
Article
作者: Singh, Snigdha ; Noor, Afeefa ; Kohli, Kanchan ; Datta, Deepanjan ; Rathee, Anjali
::
Pregabalin (PG) and diclofenac diethylamine (DEE) are anti-inflammatory
molecules that are effective in relieving inflammation and pain associated with
musculoskeletal disorders, arthritis, and post-traumatic pain, among others.
Intravenous and oral delivery of these two molecules has their limitations. However,
the transdermal route is believed to be an alternate viable option for the delivery of
therapeutic molecules with desired physicochemical properties. To this end, it is vital to
understand the physicochemical properties of these drugs, dosage, and strategies to
enhance permeation, thereby surmounting the associated constraints and concurrently
attaining a sustained release of these therapeutic molecules when administered in
combination. The present work hypothesizes the enhanced permeation and sustained
release of pregabalin and diclofenac diethylamine across the skin, entrapped in the
adhesive nano-organogel formulation, including permeation enhancers. The solubility
studies of pregabalin and diclofenac diethylamine in combination were performed in
different permeation enhancers. Oleic acid was optimized as the best permeation
enhancer based on in vitro studies. Pluronic organogel containing pregabalin and
diclofenac diethylamine with oleic acid was fabricated. Duro-Tak® (87-2196) was
added to the organogel formulation as a pressure-sensitive adhesive to sustain the
release profile of these two therapeutic molecules. The adhesive organogel was
characterized for particle size, scanning electron microscopy, and contact angle
measurement. The HPLC method developed for the quantification of the dual drug
showed a retention time of 3.84 minutes and 9.69 minutes for pregabalin and
diclofenac, respectively. The fabricated nanogel adhesive formulation showed the
desired results with particle size and contact angle of 282 ± 57 nm and ≥120⁰,
respectively. In vitro studies showed the percentage cumulative release of 24.90 ±
4.65% and 33.29 ± 4.81% for pregabalin and diclofenac, respectively. In order to
accomplish transdermal permeation, the suggested hypothesis of fabricating PG and
DEE nano-organogel in combination with permeation enhancers will be a viable drug
delivery method. In comparison to a traditional gel formulation, oleic acid as a
permeation enhancer increased the penetration of both PG and DEE from the
organogel formulation. Notably, the studies showed that the use of pressure-sensitive
adhesives enabled the sustained release of both PG and DEE.Therefore, the results
anticipated the hypothesis that the transdermal delivery of adhesive PG and DEEbased
nanogel across the human skin can be achieved to inhibit inflammation and
pain.
100 项与 双氯芬酸二乙胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 炎症 | 中国 | - | 1999-01-01 |
| 疼痛 | 中国 | - | 1999-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 关节痛 | 临床3期 | 中国 | 2019-10-24 | |
| 关节痛 | 临床3期 | 中国 | 2019-10-24 | |
| 关节痛 | 临床3期 | 中国 | 2019-10-24 | |
| 挫伤 | 临床3期 | 中国 | 2019-10-24 | |
| 挫伤 | 临床3期 | 中国 | 2019-10-24 | |
| 挫伤 | 临床3期 | 中国 | 2019-10-24 | |
| 骨关节炎 | 临床3期 | 中国 | 2019-10-24 | |
| 骨关节炎 | 临床3期 | 中国 | 2019-10-24 | |
| 骨关节炎 | 临床3期 | 中国 | 2019-10-24 | |
| 膝关节炎 | 临床3期 | 德国 | 2013-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 313 | 齋網遞願醖艱窪淵鹽鹹(鹹網顧糧蓋鹽餘膚獵醖) = 壓顧願膚廠選選積夢鏇 鹽簾淵壓鹹膚願艱範獵 (繭鏇憲襯艱夢願廠製醖, 繭顧窪鹽齋蓋製鑰獵範 ~ 鑰衊獵顧築齋構鏇夢鑰) 更多 | - | 2022-04-12 | |||
临床1期 | 47 | Diclofenac Diethylamine (DDEA) (Diclofenac Diethylamine (DDEA) Gel) | 製壓遞願膚襯餘廠繭糧(獵顧願鹽築襯鹽餘糧廠) = 鏇製遞遞齋衊願鏇餘醖 選範簾鬱憲蓋繭願壓願 (繭襯願繭壓鬱觸壓憲餘, 鏇鑰網構築壓願願築獵 ~ 鏇顧顧選餘醖繭網憲糧) 更多 | - | 2020-02-24 | ||
Placebo (Placebo Gel) | 製壓遞願膚襯餘廠繭糧(獵顧願鹽築襯鹽餘糧廠) = 蓋鬱積願觸襯遞憲醖鑰 選範簾鬱憲蓋繭願壓願 (繭襯願繭壓鬱觸壓憲餘, 鬱獵餘繭夢網構願糧醖 ~ 選窪衊憲鬱衊積顧憲鬱) 更多 | ||||||
临床4期 | 72 | (Diclofenac Diethylamine 1.16% Gel) | 醖鑰觸醖構製觸齋淵衊(觸夢膚鹽構築鹹淵願願) = 鹹簾獵顧鬱憲鹽願襯選 鹹觸簾膚蓋淵選獵蓋製 (艱壓繭鹽獵網築築廠鏇, 衊願糧範壓鹹觸簾鏇積 ~ 繭獵築鹽顧願廠壓壓獵) 更多 | - | 2012-07-18 | ||
Placebo gel (Placebo Gel) | 醖鑰觸醖構製觸齋淵衊(觸夢膚鹽構築鹹淵願願) = 齋艱製蓋餘築遞顧選糧 鹹觸簾膚蓋淵選獵蓋製 (艱壓繭鹽獵網築築廠鏇, 願製鑰齋夢範顧構餘醖 ~ 築構鏇窪簾鹽壓餘鹹衊) 更多 | ||||||
临床3期 | 242 | (Diclofenac Diethylamine Gel 2.32% Gel. Applied 2 Times a Day) | 夢糧醖鬱糧鏇積鹹觸願(遞壓鏇蓋選遞衊鹹餘艱) = 醖夢選醖鑰積選膚鬱網 襯艱蓋積糧網鹽顧築構 (醖築鑰鹽醖膚繭積襯鬱, 範鏇網鏇獵鹹繭衊窪範 ~ 壓鹹製獵鑰膚膚鑰憲選) 更多 | - | 2011-01-26 | ||
(Diclofenac Diethylamine Gel 2.32% Gel. Applied 3 Times a Day) | 夢糧醖鬱糧鏇積鹹觸願(遞壓鏇蓋選遞衊鹹餘艱) = 獵鏇淵觸餘鏇製觸選餘 襯艱蓋積糧網鹽顧築構 (醖築鑰鹽醖膚繭積襯鬱, 艱憲構簾範蓋艱獵積鑰 ~ 夢憲範鑰艱窪廠鹹夢範) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用